Pacira BioSciences (PCRX)
Develops non-opioid pain and musculoskeletal treatments built on a liposome drug-delivery platform.
$24.77
vs last close+0.66 (+2.74%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 111.51% | 44.45M shares | |
|---|---|---|---|
| 257 holders · as of Jun 30, 2026 | |||
| Insiders | 11.41% | 4.55M shares | |
| 17 holders · as of Aug 18, 2026 | |||
| Strategic holders | 10.55% | 4.21M shares | |
| 1 holder · as of Feb 14, 2022 | |||
| Adds to | 133.47% | ||
39.86M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 133.47%; nothing is left for Other.
13F, as of Jun 30, 2026
257 holders · 44.45M shares · 38 new positions · 120 increased · 85 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.71M | 16.82% | −29.5K | Aug 7, 2026 |
| Doma Perpetual Capital Management LLC | 2.78M | 6.97% | 0 | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 2.41M | 6.04% | −95.0K | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 2.10M | 5.28% | +42.6K | Aug 11, 2026 |
| State Street Corp | 2.06M | 5.17% | +140.4K | Aug 7, 2026 |
| D. E. Shaw & Co., Inc. | 1.95M | 4.89% | −32.4K | Aug 14, 2026 |
| Renaissance Technologies LLC | 1.73M | 4.35% | −91.7K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.69M | 4.24% | −92.5K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.20% | 7.02M | 13G | Apr 28, 2025 |
| Pedro Escuderoincl. DOMA Perpetual Partners GP LLC, DOMA Perpetual LO Equity Master Fund LP +5 more | 7.30% | 2.94M | 13D | Mar 12, 2026 |
| Vanguard Portfolio Management | 6.38% | 2.59M | 13G | May 1, 2026 |
| State Street Corporation | 5.20% | 2.06M | 13G | Aug 7, 2026 |
| Vanguard Capital Management | 5.15% | 2.09M | 13G | May 1, 2026 |
| Dimensional Fund Advisors LP | 5.10% | 2.06M | 13G | Apr 9, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Jonathan Sloninofficer: Chief Medical Officer | Sale | 3,040 | $23.23 | 216,384 |
| Jun 11, 2026 | Lauren Rikerofficer: Senior Vice President, Finance | Sale | 6,115 | $23.50 | 62,284 |
| Jun 4, 2026 | Kristen Williamsofficer: Chief Administrative Officer | Sale | 10,259 | $22.27 | 167,062 |
| Apr 23, 2026 | Shawn Crossofficer: Chief Financial Officer | Sale | 12,941 | $25.16 | 105,341 |
| Apr 20, 2026 | Shawn Crossofficer: Chief Financial Officer | Sale | 7,714 | $25.14 | 105,341 |
| Apr 22, 2026 | Shawn Crossofficer: Chief Financial Officer | Sale | 1,500 | $25.01 | 105,341 |
| Mar 17, 2026 | Mark Froimsondirector | Sale | 500 | $21.81 | 20,136 |
| Mar 17, 2026 | Jonathan Sloninofficer: Chief Medical Officer | Sale | 3,261 | $22.82 | 223,640 |
| Feb 2, 2026 | Kristen Williamsofficer: Chief Administrative Officer | Sale | 13,137 | $20.53 | 131,303 |
| Feb 2, 2026 | Lauren Rikerofficer: Senior Vice President, Finance | Sale | 4,000 | $20.81 | 52,313 |
House and Senate disclosures
Not reported.